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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
mesenchymal stem cell therapy decreased the number of relapses in patients with multiple 
sclerosis.  
STUDY DESIGN: Review of three randomized controlled trials from 2006-2016. 
DATA SOURCES: Two randomized control trials and one case series were found searching 
PubMed. The randomized control trials compared the number of relapses of patients undergoing 
stem cell therapy against placebo and anti-inflammatory treatment (IV methylprednisolone and 
oral prednisone). The case series compared the number of relapses patients experienced before 
and after stem cell therapy. 
OUTCOMES MEASURED: Clinical outcomes included the number of relapses patients 
experienced measured by onset of new neurological symptoms or by the presence of new 
gadolinium enhancing lesions (GELs) on MRI. 
RESULTS: Li J, Zhang D, Geng T, et al. demonstrated that recurrence frequency was 
significantly different between the two groups (p < 0.038).5 After dichotamization of the relapse 
data, it was found that for every two patients treated with human umbilical cord derived 
mesenchymal stem cells therapy for 6 weeks, 2 or more relapses were prevented when compared 
to steroid therapy (NNT = 2). Llufriu S, Sepulveda M, Blanco Y, et al. found a decrease in mean 
number of GEL between the BM-MSC group and placebo group (-2.78 + 5.89 vs 3 + 5.36, p = 
0.075).6 The relapse frequency data was evaluated as NNT and found that for every patient with 
multiple sclerosis treated with bone marrow derived stem cells for 12 months, no additional 
relapses will be prevented when compared to the placebo group (NNT = 0). Lu Z, Zhao H, Xu J, 
Zhang Z, Zhang X, et al. study suggested that HUC-MSC reduced relapse rate in MS patients by 
36.4% at 18 months post treatment compared to before treatment (1.2 + 0.5 vs 3.3 + 0.7, p < 
0.05).7  
CONCLUSIONS: The results of two RCTs and one case studies showed a decrease in the 
number of relapses patients with MS experienced after being treated with MSCs compared to 
steroids, placebo, and before therapy. 
KEY WORDS: Multiple Sclerosis, mesenchymal stem cell therapy 
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INTRODUCTION 
Multiple sclerosis (MS) is an autoimmune disease effecting the central nervous system 
(CNS). It is characterized by chronic inflammation, demyelination, gliosis (scarring), and 
neuronal loss.1 Those affected by MS experience episodes of weakness, numbness and tingling in 
their upper extremities along with loss of voluntary control of their limbs along with visual 
symptoms and incontinence issues. Patients may experience periods where they recover partial 
neuronal function but ultimately progress to permanent disabilities.2 The prevalence of MS 
worldwide is 0.1-0.2%.2 It affects approximately 2.5 million people worldwide with 350,000 
cases reported in the US alone.2 MS is a chronic disabling disease present throughout the world. 
The etiology of MS is not completely understood. Current evidence suggests a genetic 
susceptibility to the disease based on twin studies and family history. MS also has an 
autoimmune association with HLA-DR2 (human leukocyte antigen) and alleles of IL2RA (the 
interleukin-2 receptor alpha gene) and IL7RA (the interleukin-7 receptor alpha gene).2 While the 
etiology is unclear, current treatment options are used to reduce inflammation and prevent new 
flare ups. Acute episodes are treated with steroids (methylprednisolone, prednisone, or 
dexamethasone) to reduce inflammation.2 Current first line recommendations for relapse 
prevention include interferon β-1a, interferon β-1b, glatiramer acetate, fingolimod, 
teriflunomide, or dimethyl fumarate.2 If patients continue to have disease activity then providers 
may consider using natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, or 
mitoxanate.2 While these therapies aim to relieve symptoms and prevent relapse there is yet to be 
a definitive curative treatment. 
While patients may find relief from these medications, the cost of treatment is very 
expensive. The annual cost for relapse prevention medications listed above range from $51,158 
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to $ 63,806 annually.3 On top of drug costs, MS patients are 3.5 times as likely to be 
hospitalized, twice as likely to have at least 1 emergency room visit and 2.4 times as likely to 
have at least 1 visit for physical, occupational, or speech therapy. Not only do they seek care 
more frequently than the average patient but they also spend more money on medical services. In 
comparing patients with MS to non-MS patients, it was found that on average they spend on 
$4,110 on inpatient services compared to $836, $1,693 vs. $259 for radiology services, $432 vs. 
$189 for ER services, and $849 vs. $310 for office visits in a one-year period.4 These are only the 
costs patients experience for one year and this is a life-long progressively disabling condition. 
Patients with MS have more medical visits and expenses than the average patient. 
There is no current cure for multiple sclerosis. The above medications are expensive and 
do not alter the course of the condition. Mesenchymal stem cell therapy is a relatively new area 
of research in treating MS and may be helpful in preventing relapses in affected patients. This 
paper reviews two randomized control trials and a case series in evaluating if stem cells are a 
new potential therapy as a treatment option for people suffering from MS. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not mesenchymal 
stem cell therapy decreased the number of relapses in patients with multiple sclerosis.  
METHODS 
 Two randomized control trials and one case series are included in this review. The 
population consisted of males and females ages 18 and older with multiple sclerosis. Li J, Zhang 
D, Geng T, et al. compared the number of relapses between a control group receiving steroid 
treatment and the experimental group which received stem cell therapy. Both groups received the 
same treatment schedule of IV methylprednisolone for 6 weeks but the experimental group 
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received human umbilical cord derived mesenchymal stem cells (HUC-MSC) therapy three 
times a week in addition to steroids.5 The number of relapses were then compared between the 
two groups.5 Llufriu S, Sepulveda M, Blanco Y, et al study contained two randomized groups 
that received either bone marrow derived mesenchymal stem cells (BM-MSC) IV for 6 months 
or placebo. The treatment was reversed at 6 months and patients were followed for an additional 
year. The authors compared the two groups at baseline, 6 months, and 1 year.6 Lu Z, Zhao H, Xu 
J, Zhang Z, Zhang X, et al compared the relapse frequency in the same patient population before 
and 18 months after a series of five injections of HUC-MSC.7  
The studies were found searching PubMed for key words: multiple sclerosis, 
mesenchymal stem cells. Articles were chosen based on their relevance to the proposed clinical 
question and were selected only if they studied patient oriented evidence that matters (POEMs). 
Articles were published in English in peer reviewed journals between 2006 and 2016. 
Participants that were included in the studies were relapse-remitting multiple sclerosis (RRMS) 
or secondary-progressive multiple sclerosis (SPMS)5,6,7, EDSS scores between 3.0 to 8.06, and 
age between 18 and 657. Those excluded were patients with significant cardiac/renal/liver 
failure5, active or chronic infection5,6,7, or autoimmune condition unrelated to MS7. The statistics 
reported in this review include numbers needed to treat (NNT), confidence intervals, chi-squares, 
mean difference, and p-values.  See Table 1 for demographics and inclusion/exclusion criteria. 
Table 1 – Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Li5 (2014) RCT 23 25-
55 
-RRMS or 
SPMS 
- Mean EDSS 
of 5.0  
-deterioration 
of > 1.0 on 
-treated with 
cytotoxic 
medications in the 
past 3 months 
0 Human 
umbilical 
cord-derived 
mesenchymal 
stem cell 
therapy at the 
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EDSS in past 
year 
-> 2 attacks 
in the last 2 
years  
-significant cardiac, 
renal, or hepatic 
failure  
-active infection 
-severe cognitive 
decline 
-unable to 
understand and sign 
the informed 
consent 
same time as 
anti-
inflammatory 
treatment 
Llufriu6 
(2014) 
RCT 9 23-
48 
-RRMS not 
responding  
therapy for a 
year 
-ages 18 to 50 
years 
-disease 
duration of 2 
to 10 years  
-EDSS scores 
3.0 to 6.5.  
-Active or chronic 
infection 
-treatment with any 
immunosuppressive 
therapy within the 
previous 3 months or 
interferon-beta, 
glatiramer acetate or 
corticosteroids within 
30 days prior to 
randomization. 
1 Bone marrow 
derived 
mesenchymal 
stem cells 
 
Lu7 (2013) Case 
Series 
8 18-
59 
-SPMS 
-Ages 18-65 
-Duration of 
disease > 4 
years  
-EDSS score 
3.0 to 8.0 
-Failure to 
respond to 
the MS 
therapy 
-Systemic active 
disease 
-Autoimmune 
condition unrelated 
to MS or allergies; 
-Pregnant or 
possibly pregnant; 
-HIV (+), Tumor 
marker (+), brain 
tumor or BP ≥ 
200 mmHg/110 
mmHg 
0 intrathecal 
intravenous 
injections of 
human 
umbilical 
cord-derived 
stem cells 
 
OUTCOMES MEASURED  
Clinical outcomes included the number of relapses patients experienced measured by 
onset of new neurological symptoms or by the presence of new gadolinium enhancing lesions 
(GELs) on MRI. 
RESULTS  
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Li J, Zhang D, Geng T, et al. had an experimental group consisting of 13 patients with an 
average age of 42 years and a control group of 10 patients with an average age of 39 years. All 
patients had either RRMS or SPMSS. The experimental group had an average EDSS score of 7.0 
and the control group had an average score of 6.0. All patients were treated with IV 
methylprednisolone for 5 days followed by an oral prednisone taper for 2 weeks until they 
reached the maintenance dosage (5mg daily). The experimental group received HUC-MSCs once 
every 2 weeks 3 consecutive times. The authors used a chi-square to demonstrate that gender and 
type of MS had no significant effect between groups (p = 0.968). A chi-square was also 
performed on recurrence frequency data which found a significant decrease in relapse frequency 
between the two groups (p < 0.038).5 The study suggests that using HUC-MSCs with steroid 
therapy decreased relapses when compared to steroids alone. 
This review further investigated the incidence of relapses by dichotomizing the data 
found in Table 5 (Group x Relapse Incidence Crosstab) from Li J, Zhang D, Geng T, et al. 
Success was defined as one relapse or less and failure was considered if a patient had more than 
one relapse after treatment. This data was then constructed into a 2x2 table to calculate the 
control event rate (CER), experimental event rate (EER), relative and absolute risk ratio (RRR), 
absolute risk ratio (ABR), and numbers needed to treat (NNT). The results are summarized in 
Table 2 below. 
Table 2: Efficacy of HUC-MSC in Reducing Relapses Compared to Steroids 
Study CER EER RRR ABR NNT 
Li5 0.20 0.77 2.85 0.57 2 
 
Llufriu S, Sepulveda M, Blanco Y, et al. had a total of nine participants in their study, 
four of which were randomized into the placebo group and five which received the BM-MSCs. 
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The experimental group received 6 months of BM-MSC therapy and then the treatment was 
reversed for the next six months. Patients were assessed at 1, 3, 6, 7, 9, and 12 months after 
randomization. No difference was found in the demographics or gadolinium enhancing lesions at 
baseline (4.75 + 7.6 vs 4.6 + 9.7, p = 1.0). At six months, the mean difference in cumulative GEL 
was found to be difference when comparing the data at a 95% confidence interval (CI) (1.53, 
95% CI 0.53-4.42 vs 6.15, 95% CI 2.19-17.28, p = 0.064). At the end of the study there was also 
a decrease in mean number of GEL between the BM-MSC group and placebo group (-2.78 + 
5.89 vs 3 + 5.36, p = 0.075).  Four patients experienced relapses during the placebo phase. One 
patient assigned to the placebo group withdrew consent after having five relapses within the first 
three months. Three patients experienced relapses during the BM-MSC treatment period.6 While 
the study showed a decrease none of the results were statistically significant. 
This review dichotomized the data in Figure 2 (relapses and gadolinium-enhancing 
lesions during the study) from Llufriu S, Sepulveda M, Blanco Y, et al. The number of relapses 
were counted in placebo and MSC treatment groups. A 2x2 table was constructed comparing 
before and after treatment with success defined as 1 relapse or less. Patient one withdrew from 
treatment after having 3 relapses and his data was counted as a failure for both the placebo and 
control groups. A 2x2 table was constructed and used to calculate CER, EER, RRR, ABR, and 
NNT reported below in Table 3. 
Table 3: Efficacy of BM-MSC in Reducing Relapses Compared to Placebo 
Study CER EER RRR ABR NNT 
Llufriu6 0.78 0.78 0 0 0 
 
Lu Z, Zhao H, Xu J, Zhang Z, Zhang X, et al. recruited eight patients with SPMS to 
receive intrathecal IV injections of HUC-MSCs. The authors used brain and spinal MRI to 
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evaluate any decrease in volume or number of lesions before and after treatment as well as any a 
neurological assessment to detect any new neurological symptoms. The authors noted that the 
GEL lesion volume was lower 12 months after treatment and that two patients had a decrease in 
the number of lesions. The decreased GELs and reported symptoms were analyzed by using a 
mean difference to compare the same group at baseline and after treatment. Their results 
suggested that the relapse rate was reduced by 36.4% at 18 months post treatment compared to 
before treatment (1.2 + 0.5 vs 3.3 + 0.7, p < 0.05).7 The number of relapses before and after 
treatment are summarized in Table 4 below. 
Table 4: Efficacy of HUC-MSC in Reducing Relapses Before and After Treatment 
Study Relapses 
Before HUC-
MSC 
Relapses 
After HUC-
MSC 
Mean 
Relapses 
Before 
HUC-
MSC 
Mean 
Relapses 
After 
HUC-
MSC 
P-value Relapse 
Frequency 
Lu7 25 9 3.3 + 0.7 1.2 + 0.5 0.05 36.4% 
 
DISCUSSION 
Stem cell therapy is a promising new area of research for multiple chronic nervous 
disorders. Stem cells can be harvested from the bone marrow of healthy donors (BM-MSC) or 
from umbilical cord blood (HUS-MSC). Patients are treated with a preparative regiment to 
suppress the patient’s immune system. Immunosuppression with cyclosporine or tacrolimus is 
used to prevent graph versus host disease.8 Stem cells are used in this manner to currently 
provide curative treatments for leukemias, myelodysplasia, and severe aplastic anemia.8 
Umbilical cord stem cells are associated with less graft versus host disease, less HLA restriction, 
and less likely to be contaminated with herpes virus compared to other forms of stem cells.9 
HUS-MSCs are preferred over BM-MSC due to more availability and less risk of graft versus 
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host disease. Many clinical trials are being undertaken in other neuronal conditions such as ALS, 
spinal cord injury, epilepsy, Parkinson’s disease, and Alzheimer’s disease.9 Stem cells are 
currently being studied as a new therapy in the treatment of progressive degenerative 
neurological diseases. 
Stem cell therapy is not without its own risks. Most studies report very little side effects 
and demonstrate a good safety profile for the drug. Out of the three studies in this review none 
reported any adverse reactions to the therapy.  Herberts, Kwa, and Hermsen10 reviewed adverse 
reactions to stem cell therapy and found the following: rejection of cells, susceptibility to 
disease, toxicity, neoplasm formation, disease transmission, and reactivation of latent viruses. 
The most concerning of which is tumor formation. They followed a report of a 13-year-old boy 
developing a brain tumor of non-host origin four years after transplant. This is thought be due to 
the resemblance of stem cells to cancer cells with a long-life span, apoptosis resistance, and 
ability to replicate for long periods of time.10 The largest concern with stem cell therapy is 
neoplasm formation which may be a future area of research in the long-term safety profile of this 
novel therapy. 
In the United States, the government has authorized research for using existing 
embryonic stem cells but restricts federal funding for developing new stem cell lines. Stem cell 
research raises concerns on the ethical limits of science and human life. A team of scientists, 
health care providers, lawyers, and sociologists must balance the medical benefits with the 
ethical dilemmas of stem cell therapy.10 Other limitations surrounding stem cell therapy include 
not being in clinical phases and not being a FDA approved therapy. Therefore, stem cell therapy 
is not readily available yet as a treatment option is still in preclinical research phases. 
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In the three articles reviewed each found that stem cells decreased relapse rates. Li J, 
Zhang D, Geng T, et al. demonstrated that recurrence frequency was significantly different 
between the two groups (p < 0.038).5 Table 2 evaluated this data as NNT showing that for every 
two patients treated with human umbilical cord derived mesenchymal stem cell therapy for 6 
weeks, 2 or more relapses were prevented when compared to the control group. This is a small 
treatment effect that could become more significant with a larger pool of patients. Llufriu S, 
Sepulveda M, Blanco Y, et al. found a nonsignificant decrease in mean number of GEL between 
the BM-MSC group and placebo group (-2.78 + 5.89 vs 3 + 5.36, p = 0.075).6 Table 3 evaluated 
the number of relapses as a NNT; For every patient with multiple sclerosis treated with bone 
marrow derived stem cells for 12 months, no additional relapses will be prevented when 
compared to the placebo group. This may be due to the stringent criteria used to dichotomize the 
data; defining a success as one relapse or less. It is also due in part to the small sample size of 
nine patients. Lu Z, Zhao H, Xu J, Zhang Z, Zhang X, et al. found a reduction in relapse rate by 
36.4% at 18 months post treatment compared to before treatment (1.2 + 0.5 vs 3.3 + 0.7, p < 
0.05).7 All three studies found a decrease in the number of relapses participants experienced after 
treatment with mesenchymal stem cells however one of the RCTs did not translate well as NNT 
and was not statistically significant. 
This EBM review encountered difficulty in finding appropriate studies and each study 
found was limited by a small sample size. Only two RCTs and one case series were found using 
online databases for mesenchymal stem cell therapy giving limited the available data to be 
reviewed. Each article found had small sample sizes decreasing the generalizability of the 
results. More research is necessary to confirm the validity of these authors’ results and a larger 
participant group is needed to help generalize the results. Furthermore, the articles followed 
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participants for about a year which is a short amount of time for a chronic condition such as MS. 
It is unknown how long the stem cells remain effective for or the frequency of treatments needed 
to prevent relapses and an area that needs future investigation. The case series lacks 
randomization, blinding, and a comparison group making it difficult to make any generalizations 
about the effectiveness of MSCs. Also, none of the studies compared biologic therapy to MSC 
therapy. The authors only compared MSC therapy to placebo, steroids, and no treatment. It is 
unknown if MSC therapy is superior to biologics in preventing relapses in MS patients. Further 
research is needed to address these issues. 
CONCLUSION 
 The results of two RCTs and one case studies showed a decrease in the number of 
relapses patients with MS experienced after being treated with MSCs compared to steroids, 
placebo, and before therapy. However, in evaluating Llufriu et al’s study as NNT, it was found 
that for every patient with multiple sclerosis treated with bone marrow derived stem cells for 12 
months, no additional relapses will be prevented when compared to the placebo group.  Each 
study suffered from having a very small group of participants making it difficult to generalize the 
results. Repeat research is warranted with larger population sizes to support the evidence found 
in this review. The case series data is limited due to a lack of randomization, blinds, and a 
control group. The only research that focused on POEM was performed in comparing MSC 
therapy to placebo and steroids. Steroid therapy is only used for relief of acute exacerbations of 
MS and not for relapse prevention. This does not demonstrate any advantage to current therapies 
to keep MS in remission and needs to be addressed before becoming a treatment option available 
to patients. This review suggests that further research is warranted to compare MSC therapy to 
biologic therapies such as interferon, fingolimod, or glatiramer acetate. Further research is 
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necessary to help evaluate the efficacy of MSC therapy as a viable treatment option for patients 
suffering from MS.
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